Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease.
10.3988/jcn.2014.10.2.140
- Author:
Gyeong Joon MOON
1
;
Suk Jae KIM
;
Yeon Hee CHO
;
Sookyung RYOO
;
Oh Young BANG
Author Information
1. Medical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Korea.
- Publication Type:Original Article
- Keywords:
atherosclerosis;
ischemic stroke;
statin;
oxidative stress;
cholesterol
- MeSH:
Antioxidants*;
Apolipoproteins;
Atherosclerosis;
Brain Injuries;
Cholesterol;
Coenzyme A;
DNA;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors*;
Lipid Peroxidation;
Lipoproteins;
Oxidative Stress;
Oxidoreductases;
Stroke;
Rosuvastatin Calcium
- From:Journal of Clinical Neurology
2014;10(2):140-147
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND PURPOSE: Oxidative stress is involved in the pathophysiological mechanisms of stroke (e.g., atherosclerosis) and brain injury after ischemic stroke. Statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, have both pleiotropic and low-density lipoprotein (LDL)-lowering properties. Recent trials have shown that high-dose statins reduce the risk of cerebrovascular events. However, there is a paucity of data regarding the changes in the oxidative stress markers in patients with atherosclerotic stroke after statin use. This study evaluated changes in oxidative stress markers after short-term use of a high-dose statin in patients with atherosclerotic stroke. METHODS: Rosuvastatin was administered at a dose of 20 mg/day to 99 patients who had suffered an atherosclerotic stroke and no prior statin use. Blood samples were collected before and 1 month after dosing, and the serum levels of four oxidative stress markers-malondialdehyde (MDA), oxidized LDL (oxLDL), protein carbonyl content (PCO), and 8-hydroxy-2'-deoxyguanosine (8-OHdG)-were evaluated to determine the oxidation of MDA and lipids, proteins, and DNA, respectively, at both of those time points. RESULTS: The baseline levels and the degrees of reduction after statin use differed among the oxidative stress markers measured. MDA and PCO levels were associated with infarct volumes on diffusion-weighted imaging (r=0.551, p<0.05, and r=0.444, p=0.05, respectively). Statin use decreased MDA and oxLDL levels (both p<0.05) but not the PCO or 8-OHdG level. While the reduction in MDA levels after statin use was not associated with changes in cholesterol, that in oxLDL levels was proportional to the reductions in cholesterol (r=0.479, p<0.01), LDL (r=0.459, p<0.01), and apolipoprotein B (r=0.444, p<0.05). CONCLUSIONS: The impact of individual oxidative stress markers differs with time after ischemic stroke, suggesting that different oxidative markers reflect different aspects of oxidative stress. In addition, short-term use of a statin exerts antioxidant effects against lipid peroxidation via lipid-lowering-dependent and -independent mechanisms, but not against protein or DNA oxidation in atherosclerotic stroke patients.
